3.5.1.99: fatty acid amide hydrolase
This is an abbreviated version!
For detailed information about fatty acid amide hydrolase, go to the full flat file.
Word Map on EC 3.5.1.99
-
3.5.1.99
-
endocannabinoids
-
cannabinoids
-
pain
-
lipase
-
agonist
-
monoacylglycerol
-
2-arachidonoylglycerol
-
anxiety
-
analgesic
-
cannabis
-
n-acylethanolamines
-
vanilloid
-
2-arachidonoyl
-
ethanolamide
-
palmitoylethanolamide
-
carbamate
-
rimonabant
-
hyperalgesia
-
reward
-
tone
-
nociceptive
-
cannabimimetic
-
n-arachidonoylethanolamine
-
marijuana
-
anxiolytic
-
nape-pld
-
antinociceptive
-
oleoylethanolamide
-
emotional
-
neuropathic
-
delta9-tetrahydrocannabinol
-
amidase
-
amygdalar
-
medicine
-
catalepsy
-
pharmacology
-
anti-allodynic
-
anxiolytic-like
-
monoglyceride
-
cannabidiol
-
psychoactive
-
sleep-inducing
-
phytocannabinoids
-
anxiety-like
-
arachidonyl
-
monoacyl
-
capsazepine
-
aversive
-
tetrahydrocannabinol
-
drug development
-
anti-hyperalgesic
-
neuromodulatory
-
fluorophosphonate
- 3.5.1.99
-
endocannabinoids
- cannabinoids
- pain
- lipase
- agonist
- monoacylglycerol
- 2-arachidonoylglycerol
-
anxiety
-
analgesic
- cannabis
- n-acylethanolamines
-
vanilloid
-
2-arachidonoyl
- ethanolamide
- palmitoylethanolamide
- carbamate
-
rimonabant
- hyperalgesia
-
reward
-
tone
-
nociceptive
-
cannabimimetic
- n-arachidonoylethanolamine
- marijuana
-
anxiolytic
- nape-pld
-
antinociceptive
- oleoylethanolamide
-
emotional
-
neuropathic
- delta9-tetrahydrocannabinol
- amidase
-
amygdalar
- medicine
- catalepsy
- pharmacology
-
anti-allodynic
-
anxiolytic-like
- monoglyceride
- cannabidiol
-
psychoactive
-
sleep-inducing
-
phytocannabinoids
-
anxiety-like
-
arachidonyl
-
monoacyl
-
capsazepine
-
aversive
- tetrahydrocannabinol
- drug development
-
anti-hyperalgesic
-
neuromodulatory
- fluorophosphonate
Reaction
Synonyms
AAH, anandamide amidohydrolase, AtFAAH, endocannabinoid-degrading enzyme, FA amide hydrolase, FAAH, FAAH-1, FAAH-2, fatty acid amide hydrolase, fatty-acid amide hydrolase, hFAAH, oleamide hydrolase
ECTree
Advanced search results
Application
Application on EC 3.5.1.99 - fatty acid amide hydrolase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
medicine
-
FAAH is a promising target for the treatment of several central and peripheral nervous system disorders, such as anxiety, pain and hypertension
medicine
there is significant therapeutic potential for FAAH inhibitors as analgesic, neuroprotective, anti-inflammatory and anti-anxiety drugs, and as agents for the treatment of metabolic and sleep disorders
medicine
fatty acid amide hydrolase is a promising target for the development of drugs to treat neurological diseases
medicine
-
fatty acid amide hydrolase is involved in many human diseases, particularly cancer, pain and inflammation as well as neurological, metabolic and cardiovascular disorders. Therefore, FAAH is an attractive target for the development of low-molecular-weight inhibitors as therapeutics, which requires robust assays that can be used for high-throughput screening of compound libraries. A highly sensitive fluorescence-based assay with the substrate N-(6-methoxypyridin-3-yl)decanamide is described
medicine
inhibition of fatty acid amide hydrolasis is considered a powerful approach to enhance the endocannabinoid signalling and is a potential target for the treatment of neurological disorders such as anxiety or depression, or of inflammatory process
medicine
-
inhibitors of fatty acid amide hydrolase may represent new drug candidates for the treatment of inflammation
medicine
there is evidence indicating that enhancing the endocannabinoid (eCB) tone has therapeutic potential in several brain disorders. The inhibition of endocannabinoid degradation by fatty acid amide hydrolase blockade, is the best-known option to increase N-acyl-ethanolamines-mediated signaling. By showing the efficacy of intranasal FAAH inhibition, evidence is provided that nose-to-brain delivery is a suitable alternative to enhance brain endocannabinoid tone for the treatment of neurodegenerative disorders and improve patients' compliance